ICN to Expand Testing, Hire More Researchers
- Share via
ICN Pharmaceuticals Inc. said Monday that it will step up research and development spending on antiviral and anticancer drugs and hire a dozen researchers.
The Costa Mesa drug maker said it expects to spend about $50 million over the next year or two on clinical trials, a “substantial” increase in research and development investments.
ICN will fund the additional investment with royalties it receives from Schering-Plough Corp., which has worldwide rights to market ICN’s ribavirin for hepatitis treatment. ICN estimates 1999 royalties from Schering-Plough at more than $100 million.
With the infusion of new funds, ICN said its researchers will begin studies that encompass clinical trials of anticancer drugs and antivirals that are more effective and less toxic than ribavirin.
More to Read
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.